Freenome, developer of checks that determine early indicators of most cancers from a small pattern of affected person blood, goes public in a merger deal that can infuse the corporate with $330 million to help a pipeline that would yield its first commercialized check in 2026.
The early most cancers detection firm is merging with Perceptive Capital Options Corp, a particular objective acquisition firm (SPAC) sponsored by an affiliate of Perceptive Advisors, the corporations introduced Friday. The mixed firm will take the Freenome identify. When the deal closes, Freenome’s inventory is anticipated to commerce on the Nasdaq beneath the inventory image “FRNM.”
Brisbane, California-based Freenome is a part of a bunch of corporations growing checks that detect organic and genetic indicators of most cancers by analyzing a small pattern of affected person blood, a so-called liquid biopsy. Freenome’s platform know-how makes use of synthetic intelligence and machine studying strategies to research samples and determine most cancers alerts. Such checks are supposed to detect most cancers on the earliest phases of illness when remedy has a larger likelihood of success. Early most cancers detection represents a $50 billion market alternative, Freenome mentioned in an investor presentation.
A colorectal most cancers check is Freenome’s most superior product candidate. This check, known as SimpleScreen, is presently beneath FDA assessment with a regulatory determination anticipated in mid-2026. Freenome’s major competitor in colorectal most cancers detection will likely be Guardant Well being, whose Defend check was the primary FDA-approved liquid biopsy for any such most cancers. Precise Sciences was anticipated to compete with its personal check, however scientific trial outcomes from a pivotal research have been disappointing. Subsequently, Precise struck a take care of Freenome in August, paying $75 million up entrance for U.S. rights to SimpleScreen for the only indication of colorectal most cancers screening.
The Precise Sciences deal permits Freenome to maintain rights to colorectal most cancers screening as a part of a multi-cancer detection check it’s growing to display screen for greater than 10 cancers from a pattern of affected person blood. Roche, which already has an current relationship with Freenome as an investorfinal month reached a deal securing rights to commercialize the corporate’s “kitted” multi-cancer early detection checks exterior of the U.S. Kitted checks bundle the assay and software program collectively to allow processing and evaluation of a pattern with no need a centralized lab. This deal got here with a $75 million upfront fairness funding in Freenome; one other $134 million is tied to the achievement of milestones. Freenome retains rights to U.S. multi-cancer early detection testing in addition to U.S. rights to kitted checks.
Freenome is pursuing a “versioning technique” during which assay and algorithm enhancements will likely be integrated into later variations of its checks. The regulatory submission presently beneath FDA assessment is for model 1 of SimpleScreen. The corporate expects a regulatory submission for model 2 will likely be prepared by the center of subsequent yr. The investor presentation provides a peek into these knowledge, exhibiting 75% sensitivity for detecting stage I colorectal most cancers; sensitivities for superior adenoma and high-grade dysplasia have been 22% and 44% respectively. Whereas these marks prime the outcomes reported for model 2 of Guardant’s Defend, William Blair analyst Andrew Brackmann mentioned in a analysis be aware that the model 2 knowledge for SimpleScreen is the ultimate scientific validation knowledge and never the pivotal knowledge anticipated to be submitted to the FDA.
“We, not surprisingly, have questions concerning how this research was run, the place the cancers are from, and so on., however even nonetheless, outcomes do present some good enchancment versus v1,” Brackmann mentioned.
Guardant’s Defend has first mover benefit out there, projected to do greater than 80,000 checks this yr, Leerink Companions analyst Puneet Souda mentioned in a analysis be aware. With the second model of SimpleScreen not anticipated to be filed till the second half of subsequent yr, Guardant has time to enhance its subsequent check, Defend model 3. However Leerink sees the marketplace for liquid biopsies as giant, with about 11 million average-risk people keen to be screened with a blood check however not a colonoscopy. That leaves room for a number of rivals, Souda mentioned.
Since its 2014 founding, Freenome had raised greater than $1.3 billion, the corporate mentioned within the investor presentation. The SPAC merger is anticipated to infuse the corporate with about $330 million. That sum breaks all the way down to $90 million from a belief account held by Perceptive Capital Options and a $240 million non-public funding in public fairness (PIPE) led by Perceptive Advisors and RA Capital. The traders within the PIPE will buy 24 million Freenome shares on the worth of $10 every.
Including Freenome’s personal funds, which incorporates funds from the Precise Sciences and Roche offers, the corporate expects to have greater than $1.3 billion whole when the merger closes, in line with the presentation. Proceeds from the transaction and money readily available will likely be utilized towards product growth, scientific testing, and commercialization actions.
The Freenome and Perceptive Capital Options boards of administrators have accepted the merger, which is anticipated to shut within the first half of 2026. The deal nonetheless wants the approval of shareholders of each corporations.
Photograph: MilosJokic, Getty Photographs
